Cite
HARVARD Citation
Kansal, A. et al. (2019). Cost‐effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA‐REG OUTCOME trial1. Diabetic medicine. 36 (11), pp. 1494-1502. [Online].